Remission induction using alemtuzumab can permit chemotherapy-refractory chronic lymphocytic leukemia (CLL) patients to undergo allogeneic stem cell transplantation

Leukemia and Lymphoma

Volumn 45, Issue 12, 2004, Pages 2455-2458

  Knauf, Wolfgang ^a,d   Rieger, Kathrin ^a   Blau, Wolfgang ^a   Hegenbart, Ute ^b   Von Gruenhagen, Ulrich ^c   Niederwieser, Dietger ^b   Thiel, Eckhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Oncology Outpatient Department   (Germany)

^d Bethanien Krankenhaus Frankfurt   (Germany)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Stem cell transplant

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; FLUDARABINE; THYMOCYTE ANTIBODY; TREOSULFAN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; CANCER REGRESSION; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HEPATOMEGALY; HLA MATCHING; HUMAN; LUNG ASPERGILLOSIS; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 11444258790     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400005346     Document Type: Article

References (17)

1. Dyer, M.J., Kelsey, S.M., Mackay, H.J., Emmett, E., Thornton, P., Hale, G., et al. (1997) "In vivo 'purging' of residual disease in CLL with Campath-1H", British Journal of Haematology, 97, 669-672.
2. Kennedy, B., Rawstron, A., Carter, C., Ryan, M., Speed, K., Lucas, G. and Hillmen, P. (2002) "Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia", Blood, 99, 2245-2247.
3. Chan, K.W., Bekassy, A.N., Ha, C.S., Nunez, C., Alvegard, T.A. and Sallerfors, B. (1999) "Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity", Bone Marrow Transplantation, 23, 849-851.
4. Carella, A.M., Champlin, R., Slavin, S., McSweeney, P. and Storb, R. (2000) "Mini-allografts: ongoing trials in humans", Bone Marrow Transplantation, 25, 345-350.
5. Storb, R.F., Champlin, R., Riddell, S.R., Murata, M., Bryant, S. and Warren, E.H. (2001) "Non-myeloablative transplants for malignant disease", Hematology (American Society Hematology Educational Program), 375-391.
6. Lush, R.J., Haynes, A.P., Byrne, J., Cull, G.M., Carter, G.I., Paglicua, A., et al. (2001) "Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+ / -fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion", Cytotherapy, 3, 203-210.
7. Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., et al. (2000) "In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation", Blood, 96, 2419-2425.
8. Hale, G., Jacobs, P., Wood, L., Fibbe, W.E., Barge, R., Novitzky, N., et al. (2000) "CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells", Bone Marrow Transplantation, 26, 69-76.
9. Clarke, E., Potter, M.N., Hale, G., Waldmann, H., Lankester, A., Cornish, J.M., et al. (1998) "Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34 + cell selection followed by Campath-1M; effect on CD34 + cells and progenitor cell recoveries", Bone Marrow Transplantation, 22 117-124.
10. Clarke, E., Potter, M.N., Oakhill, A., Cornish, J.M., Steward, C.G. and Pamphilon, D.H. (1997) "A laboratory comparison of T cell depletion by CD34 + cell immunoaffinity selection and in vitro Campath-1M treatment: clinical implications for bone marrow transplantation and donor leukocyte therapy", Bone Marrow Transplantation, 20, 599-605.
11. Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., et al. (2002) "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study", Blood, 99, 3554-3561.
12. Rai, K., Freter, C.B., Mercier, R.J., Cooper, M.R., Mitchell, B.S., Stadtmauer, E.A., et al. (2002) "Alemtuzamab in previously treated chronic lymphocytic leukemia patients who had also received fludarabine", Journal of Clinical Oncology, 20, 3891-3897.
13. Casper, J., Knauf, W., Kiefer, T., Wolff, D., Steiner, B., Hammer, U., et al. (2004) "Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoetic stem cell transplantation", Blood, 103, 725-731.
14. Cheson, B.D., Bennet, J.M., Grever, M., Kay, N., Keating, M., O'Brien, S. and Rai, K. (1996) "National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment", Blood, 87, 4990-4997.
15. Rieger, K., von Gruenhagen, U., Fietz, T., Thiel, E. and Knauf, W. (2004) "Efficacy and tolerability of alemtuzumab (Campath-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia - change of regimen needed?", Leukemia Lymphoma, 45, 345-349.
16. Michallet, M., Archimbaud, E., Bandini, G., Rowlings, P.A., Deeg, H.J., Gahrton, E., et al. (1996) "HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia", Annals of Internal Medicine, 124, 311-315.
17. Khouri, I.F., Przepiorka, D., van Besien, K., O'Brien, S., Palmer, J.L., Lerner, S., et al. (1997) "Allogeneic blood or marrow transplantation for chronic lymphocytic, leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease", British Journal of Haematology, 97 466-473.